✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals

Norris Medicines Ltd.

NORRIS

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹15 Cr.
P/E
0.00

Norris Medicines Ltd.

  • Norris Medicines
  • Emmessar Biotech&Nut
  • Saroja Pharma Ind

FAQs on Norris Medicines Ltd. Shareprice

Norris Medicines has given better returns compared to its competitors.
Norris Medicines has grown at ~15.68% over the last 2yrs while peers have grown at a median rate of 0.89%

Norris Medicines is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Norris Medicines is 0.0, while 3 year average PE is -0.05.
Also latest EV/EBITDA of Norris Medicines is 0.0 while 3yr average is 100.

View FAQ's On Business

Growth Table

  • Norris Medicines Ltd.
  • Emmessar Biotech&Nut
  • Saroja Pharma Ind

Balance Sheet

  • Norris Medicines Ltd.
  • Emmessar Biotech&Nut
  • Saroja Pharma Ind

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Norris Medicines Ltd.
  • Emmessar Biotech&Nut
  • Saroja Pharma Ind

Cash Flow

  • Norris Medicines Ltd.
  • Emmessar Biotech&Nut
  • Saroja Pharma Ind

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Norris Medicines Ltd.
  • Emmessar Biotech&Nut
  • Saroja Pharma Ind

Quarterly Results

  • Norris Medicines Ltd.
  • Emmessar Biotech&Nut
  • Saroja Pharma Ind

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Norris Medicines Ltd. Financials

Norris Medicines balance sheet is weak and might have solvency issues

Yes, The net debt of Norris Medicines is increasing.
Latest net debt of Norris Medicines is ₹21.51 Crs as of Mar-25.
This is greater than Mar-24 when it was ₹21.46 Crs.

The profit is oscillating.
The profit of Norris Medicines is -₹1.19 Crs for TTM, -₹1.24 Crs for Mar 2025 and -₹1.19 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Norris Medicines latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech